Analysts are weighing in on obesity-device maker EnteroMedics Inc (NASDAQ:ETRM), stem cell company Athersys, Inc. (NASDAQ:ATHX) and cancer vaccine maker Inovio Pharmaceuticals Inc (NASDAQ:INO), with price targets ranging from 164% to 197% upside.
In a research note issued today, Roth Capital analyst Chris Lewis reiterated a Buy rating on shares of Enteromedics, with a price target of $3.00, which implies an upside of approx 18o% from current levels. The note follows ETRM’s fourth-quarter business update, which was released yesterday morning.
Lewis noted, “ETRM’s 4Q sales of $149k beat our projection of $75k. We estimate 10 implants were completed in 4Q, above our projection of 5 and up from 4 implants in the prior quarter. 4Q net loss per share of ($0.95) was wider than our stock split-adjusted projection of ($0.81). Gross margin of 52% beat our projection of 45% while operating spend of $7.6 million (up 25% yoy, 26% qoq) was above our projection of $5.7 million.”
“While ETRM’s early commercial metrics are encouraging with over 50 trained centers and 80 physicians since launch, ETRM has narrowed its commercial focus to 12 key centers in 10 states that are expected to provide strong surgeon support and facilitate a more patient friendly cash pay environment,” the analyst opined.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Chris Lewis has a yearly average return of -4.5% and a 35.7% success rate. Lewis has a -71.6% average return when recommending ETRM, and is ranked #3229 out of 3640 analysts.
Athersys shares jumped nearly 17% today after the company announced that the one-year follow-up data from the phase II stroke study showed that patients receiving MultiStem continued to improve and had a statistically significant higher rate of “Excellent Outcome” versus placebo.
Reacting was Maxim analyst Jason Kolbert, which reiterated a Buy rating on Athersys, with a price target of $5.00, which implies an upside of 197% from current levels.
Kolbert noted, “It’s all in the data. Athersys continues to demonstrate that MultiStem has a meaningful clinical benefit in patients who have suffered an ischemic stroke and may extend the therapeutic window to 36 hours.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a yearly average return of -20.2% and a 25.8% success rate. Kolbert has a -0.8% average return when recommending ATHX, and is ranked #3637 out of 3640 analysts.
Inovio Pharmaceuticals Inc
Inovio announced yesterday that its synthetic Zika virus vaccine had induced robust and durable antibody and killer T cell responses in mice. Analyst Yi Chen of H.C. Wainwright views the news positively since it further validates Inovio’s SynCon technology platform.
Furthermore, the analyst reminds investors that Inovio’s end-of-Phase-2 meeting with the FDA is likely to occur in 1Q 2016 to discuss the design of the proposed Phase 3 trial of VGX-3100 for the treatment of cervical dysplasia.
Chen reiterated a Buy rating on shares of Inovio Pharmaceuticals, with a price target of $17, which implies an upside of 164% from current levels.
According to TipRanks.com, analyst Yi Chen has a yearly average return of -26.0% and a 26.1% success rate. Chen has a -0.9% average return when recommending INO, and is ranked #3516 out of 3640 analysts.
As of this writing, all the 5 analysts polled by TipRanks rate Inovio stock a Buy. With a return potential of 168%, the stock’s consensus target price stands at $17.50.